APA (7th ed.) Citation

A, L., L, P., C, B., P, G., B, X., C, R. N., . . . V, G. (2022). Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia. Annals of hematology, 101(10), 2263. https://doi.org/10.1007/s00277-022-04932-6

Chicago Style (17th ed.) Citation

A, Luna, et al. "Real-life Analysis on Safety and Efficacy of Asciminib for Ponatinib Pretreated Patients with Chronic Myeloid Leukemia." Annals of Hematology 101, no. 10 (2022): 2263. https://doi.org/10.1007/s00277-022-04932-6.

MLA (9th ed.) Citation

A, Luna, et al. "Real-life Analysis on Safety and Efficacy of Asciminib for Ponatinib Pretreated Patients with Chronic Myeloid Leukemia." Annals of Hematology, vol. 101, no. 10, 2022, p. 2263, https://doi.org/10.1007/s00277-022-04932-6.